This review summarizes epidemiology, clinical phenotypes, risk factors, and prevention of sudden cardiac death in young patients with hypertrophic cardiomyopathy.
Guides risk assessment in young HCM patients; leaves open need for prospective validation of prevention strategies.
Hypertrophic cardiomyopathy is a common, inherited heart disease with a heterogeneous clinical presentation and natural history. Recently, advances in diagnosis and treatment options have been instrumental in decreasing the frequency of adverse clinical events; however, complete elimination of sudden cardiac death still remains an elusive gain. This article discusses several aspects of this condition in the young: epidemiology, clinical phenotypes, risk factors, prevention of sudden cardiac death, and risks of athletic participation.
No takes yet. Share an insight, caveat, or question.
Maully J. Shah (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: